Accueil   Diary - News   All news VALBIOTIS obtains the European patent for VALEDIA®

VALBIOTIS obtains the European patent for VALEDIA®

VALBIOTIS a French research and development company committed to scientific innovation for preventing and combating metabolic diseases, announces
the obtention of the European patent for TOTUM-631.

 

This patent directly covers the active substance of VALEDIA® for use in 38 European countries on the prediabetes and metabolic diseases market, including type 2 diabetes and NAFLD. After obtaining the US patent in 2018, VALBIOTIS’ industrial property for VALEDIA® is now protected on its two main global markets (Europe and the United States). These markets have similar-sized prediabetic populations, each of which exceeds 80 million people2,3.

 

 

Read the press release